Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an
Acta Pharmaceuticals has secured $24m in seed funding for advancing a drug pipeline focused on early intervention and prevention of Alzheimer’s disease (AD), including the clinical progression of its lead candidate, GSM-779690T.